Srs Capital Advisors, Inc. Stoke Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 173 shares of STOK stock, worth $2,140. This represents 0.0% of its overall portfolio holdings.
Number of Shares
173Holding current value
$2,140% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
117Shares Held
55.6MCall Options Held
14KPut Options Held
8.8K-
Skorpios Trust10.8MShares$134 Million99.89% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$66.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.72MShares$58.4 Million4.16% of portfolio
-
Baker Bros. Advisors LP New York, NY4.37MShares$54 Million0.78% of portfolio
-
Rtw Investments, LP New York, NY4.22MShares$52.3 Million0.95% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $488M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...